Novel Anticoagulants Achieve Rapid Market Penetration despite Higher Costs AARP Public Policy Institute

Novel Anticoagulants Achieve Rapid Market Penetration despite Higher Costs

Full Report

(PDF) People with atrial fibrillation are five times more likely to suffer a stroke than the wider population and are often prescribed anticoagulants to reduce their elevated risk. Anticoagulants prevent blood clots from forming when irregular heart rhythms caused by atrial fibrillation allow blood to pool in the heart. Warfarin, an oral anticoagulant that was originally approved in 1954 and is widely available in generic form, was, until relatively recently, the standard treatment for stroke prevention in patients with atrial fibrillation. In October 2010, novel oral anticoagulants (or NOACs, marketed as Pradaxa, Xarelto and Eliquis) began entering the market as an alternative to warfarin. NOACs have a different mechanism of action and do not require frequent monitoring or dose adjustments that warfarin does. By the end of 2014, just four years after the first of these novel oral anticoagulants received FDA approval for the prevention of stroke among patients with nonvalvular atrial fibrillation, approximately 60 percent of patients taking daily oral anticoagulants for this purpose were using NOACs. Although it was not until 2019, however, that sufficient evidence had accumulated to update the atrial fibrillation treatment guidelines to explicitly recommend NOACs as the preferred alternative to warfarin. Significantly, NOACs were priced substantially higher than existing therapies -- approximately 20 times more expensive. As a result, following the introduction of NOACs to the marketplace, total annual per capita spending (i.e., out-of-pocket and plan paid amounts) on oral anticoagulants among newly treated atrial fibrillation patients increased dramatically—growing from a couple hundred dollars per year to several thousand dollars per year for some patients. NOAC Usage This study looks at commercially insured adults ages 50 to 64, and Medicare Advantage enrollees ages 65 and older, with atrial fibrillation who filled a new prescription for an oral anticoagulant between 2010 and 2014. This period includes the final nine months before NOACs began entering the market. Three NOACs entered the market during the study period: dabigatran (10/19/2010; sold as Pradaxa), rivaroxaban (11/04/2011; sold as Xarelto), and apixaban (12/28/2012; sold as Eliquis). During the nine months before NOACs began to enter the market, all index fills (the first time a new prescription is filled) were for warfarin. Over the five-year study period, NOACs became more popular than warfarin, particularly among younger adults. By the end of 2014, NOACs accounted for 79 percent of index fills for adults ages 50 to 64 on commercial plans and 47 percent of index fills for Medicare Advantage enrollees ages 65 and older. NOAC Costs Over the study period, annual out-of-pocket spending on oral anticoagulants approximately tripled for commercial enrollees ages 50 to 64 and quintupled for Medicare Advantage enrollees ages 65 and older. This increase translated into an added out-of-pocket burden of approximately $300 to $400 per year for patients who were adherent to their anticoagulant treatment. These out-of-pocket spending increases, while substantial, were dwarfed by the increases in annual plan spending on oral anticoagulants. Among adults ages 50 to 64 on commercial plans who adhered to their treatment, spending grew from $106 per patient per year to $2,784 per patient per year. This represents a jump from 43 percent of the total cost of treatment to 86 percent of the total cost. Among adherent Medicare Advantage enrollees ages 65 and older, plan spending grew from $104 per patient per year to $1,572 per patient per year—a jump from 53 percent of the total cost to 75 percent of the total cost. Indeed, health plans paid a disproportionately large share of the additional expense for NOACs. By the end of the study period, health plans were spending 15 to 25 times more per patient per year on anticoagulants than they were before NOACs entered the market. Higher plan spending is typically passed on to consumers via higher premiums, higher deductibles, or higher out-of-pocket expenses for other products and services. (The extent to which this burden was passed on to consumers could not be discerned from these data.) Suggested citation: Gillespie, Catherine, and Leigh Purvis. Novel Anticoagulants Achieve Rapid Market Penetration despite Higher Costs. Washington, DC: AARP Public Policy Institute, June 24, 2021.

Search PPI

Find the Public Policy Institute content you are looking for by entering in search terms below. News Alerts Sign up for alerts on the latest research, events and videos on policy issues. Subscribe

A State Scorecard on Long-Term Services and Supports for Older Adults, People with Physical Disabilities, and Family Caregivers Aging Demographics

One in Three Americans is Now 50 or Older

By 2030, one out of every five people in the United State will be 65-plus. Will your community be ready? Cancel You are leaving AARP.org and going to the website of our trusted provider. The provider’s terms, conditions and policies apply. Please return to AARP.org to learn more about other benefits. Your email address is now confirmed. You'll start receiving the latest news, benefits, events, and programs related to AARP's mission to empower people to choose how they live as they age. You can also by updating your account at anytime. You will be asked to register or log in. Cancel Offer Details Disclosures

Close In the next 24 hours, you will receive an email to confirm your subscription to receive emails related to AARP volunteering. Once you confirm that subscription, you will regularly receive communications related to AARP volunteering. In the meantime, please feel free to search for ways to make a difference in your community at Javascript must be enabled to use this site. Please enable Javascript in your browser and try again.